AMDL, Inc., Retains Porter, LeVay & Rose.Business Editors TUSTIN, Calif.--(BUSINESS WIRE)--June 29, 2001 AMDL AMDL Abstract Module Description Language AMDL Approximate Minimum Description Length , Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: AMDD AMDD Agile Model-Driven Development (software development) AMDD Assembly and Maintenance Definition Document AMDD Air and Missile Defense Division AMDD Aggressive Model-Driven Design ), a developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that it has retained Porter, LeVay & Rose, Inc., as its investor relations Investor relations The process by which the corporation communicates with its investors. counsel. AMDL's primary product is DR-70(R), a non-invasive blood test that has been shown in clinical trials to detect the presence of 13 or more cancers simultaneously. Porter, LeVay & Rose, based in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , is a 30-year-old, full-service public relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most firm that represents a wide variety of public and private companies and financial institutions in the United States and abroad. Gary L. Dreher, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AMDL, Inc., said, "We are pleased that Porter, LeVay & Rose will be helping us communicate with the investment community, our shareholders and the business news media. Our goal is to heighten the company's visibility and shareholder value as we proceed with the worldwide marketing and additional clinical trials of DR-70." Michael J. Porter, president of Porter, LeVay & Rose, said, "We are pleased to add AMDL, Inc., to our roster of growth companies, and look forward to informing and educating the financial community and news media about the company's life-saving, proprietary products." AMDL, Inc., headquartered in Tustin, CA, is the inventor and developer of the DR-70 cancer test, a non-invasive blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers simultaneously 84 percent of the time overall. DR-70 is made available to U.S. physicians and laboratories through a "research use only" labeling exemption. Clinical trials have been conducted in China, Canada, Taiwan and Turkey. Cancers that can be detected by the test are lung, colon, breast, stomach, liver, rectum, ovary ovary, ductless gland of the female in which the ova (female reproductive cells) are produced. In vertebrate animals the ovary also secretes the sex hormones estrogen and progesterone, which control the development of the sexual organs and the secondary sexual , cervix, esophagus, thyroid, pancreas, trophoblast trophoblast /tro·pho·blast/ (tro´fo-blast) the peripheral cells of the blastocyst, which attach the blastocyst to the uterine wall and become the placenta and the membranes that nourish and protect the developing organism. and malignant lymphoma. DR-70 is a non-invasive test that can detect cancer in these various organs using a single tube of blood. More information about AMDL and its additional products can be obtained at www.amdlcorporate.com. Forward-Looking Statements: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion